IBM stock has dropped 19% since July 14 following weak Q2 earnings that missed revenue estimates. Susquehanna analyst James Friedman raised his price target on the stock to $235 from $225 but maintained a Neutral rating. IBM's quantum computing division is drawing growing attention, though it currently generates very little revenue. A senior IBM executive sold roughly $5.75 million worth of stock on August 26, and the annual Quantum World Congress in September is viewed as a key upcoming catalyst for the shares.

IBM stock opened at $235.78 on Monday, trading near its 52-week low of $199.19 and well below its 52-week high of $332.46. The stock has fallen 19% since July 14, a period during which the S&P 500 gained 2.1%. That divergence underscores that IBM's decline has been driven largely by company-specific factors rather than broad market weakness.

Earnings Miss Sparks the Slide

The decline began with a record single-day plunge after IBM pre-announced its Q2 results. The company reported earnings of $2.93 per share, matching estimates, but revenue of $17.16 billion fell short of the $17.46 billion consensus. Revenue rose just 1.1% year over year.

One factor weighing on the business is customers shifting budgets toward AI hardware, pulling spending away from IBM's traditional offerings. The shift reflects a broader enterprise spending reallocation across the technology industry, as companies direct capital toward AI infrastructure — a market where IBM competes less directly than several peers — at the expense of legacy software and services budgets of the kind IBM relies on.

Quantum Gets the Spotlight

With its core business lines under pressure, IBM's quantum computing division has become a focal point for investors. Susquehanna analyst James Friedman highlighted IBM's acquisition of HRL Laboratories as well as a partnership with the Commerce Department to build Anderon, a standalone quantum chip foundry.

IBM has been researching quantum computing since before 2000 and has contributed to major scientific breakthroughs. That longevity places IBM among the most established players in a field where governments and large technology companies alike have committed significant public funding to quantum research and domestic chip production. However, the division still generates minimal revenue, and broader commercialization depends on major technological advances expected before 2030 — meaning the near-term investment case rests heavily on IBM's established software, consulting, and infrastructure businesses while quantum remains a long-duration option.

Friedman raised his price target on IBM to $235 from $225 while keeping his Neutral rating. He pointed to the annual Quantum World Congress in late September as a near-term catalyst for renewed interest in the technology.

He also flagged other moving parts: a renewed software focus in IBM's consulting arm following a new leadership appointment, limited Red Hat growth due to passing server supply constraints, and a mainframe revenue delay story in which 40% of deals that slipped in Q2 closed early in Q3. Whether the remaining slipped mainframe deals close in coming quarters is a concrete metric investors can track in IBM's Q3 report, alongside any quantum announcements from the September congress.

Insider Sale and Institutional Moves

On August 26, SVP Robert David Thomas sold 25,000 IBM shares at an average price of $230.32, for a total of $5.76 million. The sale reduced his ownership in the company by 34.34%, leaving him with 47,800 shares. Insider sales can reflect personal financial planning as well as sentiment, so a single transaction like this is difficult to interpret on its own.

On the institutional side, several firms added to their positions during Q2. New Republic Capital raised its stake by 144%, while Daiwa Securities Group increased its holdings to 251,572 shares worth $70.7 million. Institutional investors and hedge funds now own 58.96% of IBM stock, indicating that professional money continues to hold substantial exposure to the shares even after the summer sell-off.

IBM's average analyst rating sits at "Moderate Buy" with an average price target of $265.40. Sixteen analysts have a Buy rating, eleven have Hold, and one has Sell. Barclays holds an Overweight rating with a $262 target, and JPMorgan holds an Overweight rating with a $250 target.

IBM's next quarterly dividend of $1.69 per share is scheduled for payment on September 10.

Source: CoinCentral